To determine whether aspirin has a clinical benefit in the prevention of arterial thromboembolism and its consequences.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
Double-blind, placebo-controlled, multicenter trial of 303 patients at 10 centers.
Assignment into the medical and surgical groups was made by the responsible physician based on the patients' baseline clinical and laboratory evaluation. Each group was then independently randomized (after surgery in the surgical group). Patients randomized to aspirin received 650 mg twice daily. Blinded follow-up evaluations were done at 4-week intervals during the first 6 months following hospital discharge and every 3 months thereafter through 24 months. At each follow-up visit, the patient was interviewed and examined by a neurologist and blood, urine, and stool tests were performed.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Overall mortality, stroke-related mortality, retinal infarction, nonfatal cerebral infarction.|
|Secondary||TIAs pre- and post-randomization.|